Life Sciences & Healthcare Innovation Hub

whirling blurry lights
Our innovation hub for life sciences and healthcare is a demonstration of Cooley’s enduring commitment to the industry. It serves as a centralized point from which to access the insights and unparalleled experience of leading legal thinkers from across the firm and around the world.
  • Life Sciences ESG Reporting Practices 

    For life sciences companies, ESG reporting is often a particularly perplexing subject. Investor focus on ESG matters is generally a more recent phenomenon for industry companies that also often are unsure which ESG topics are relevant to their business, especially earlier-stage companies. We have prepared this report to help life sciences companies begin to answer such questions and provide insight into industry disclosure practices.

  • Join Cooley at the 2022 BIO International Convention 

    Cooley is proud to once again chair the digital health track at the BIO International Convention, which offers ample opportunities to connect with peers and others who can help you achieve your business goals. Cooley partners are among the global thought leaders addressing critical topics at the intersection of science, business and policy.

  • Staying Connected to Capital and Investors 

    California Life Sciences Bulletin: Medtech Spotlight

    “In Cooley’s Q4 2021 Venture Financing Report, the firm reported that it handled 82 disclosable financings of life sciences companies, representing more than $5.2 billion of invested capital. Deal sizes spiked, with an average deal size of more than $63 million in the quarter. Meanwhile, in a signal of investor caution, the percentage of life sciences transactions structured in tranches increased to more than 17% of deals, doubling from the prior quarter.”

  • Medtech Primer on the FDA Regulatory Landscape 

    California Life Sciences Bulletin: Medtech Spotlight

    “Medtech companies are subject to FDA regulation as medical device manufacturers if their products satisfy the ‘device’ definition in the Federal Food, Drug and Cosmetic Act (FDCA). As that definition explains, if a product is intended to diagnose, cure, mitigate, treat or prevent a disease, or is intended to affect the structure or any function of the body, it is regulated by FDA as either a drug or a device. If the product achieves its primary intended purpose through chemical or metabolic means, it is a drug; all other such medical products are devices under the FDCA.”

  • ×
  • Texas Life Science Forum 

    Rice Alliance and BioHouston will host the 11th Annual Texas Life Science Forum on Tuesday, November 8, 2022. The Texas Life Science Forum, co-hosted by BioHouston and Rice Alliance, is the premier life science and healthtech event in Texas that brings together members from industry, emerging life science companies, academic and investors.

  • Roadmap for an IPO: Preparing for the Market Return 

    In this on-demand webcast, Cooley partner Eric Jensen joins a panel of private equity and venture capital investors, company executives, and advisers to discuss preparing for an initial public offering as the markets begin to open back up.

  • ESG Forum 2022 

    Alongside panelists from the American College Cary M. Maguire Center for Ethics in Financial Services and the New York State Bar Association’s International Section, Cooley partner Brad Goldberg examines the rapidly evolving landscape of corporate environmental, social and governance reporting, including the intersection of mandatory and voluntary disclosure regimes.

  • Join Cooley at the 2022 BIO International Convention 

    Cooley is proud to once again chair the digital health track at the BIO International Convention, which offers ample opportunities to connect with peers and others who can help you achieve your business goals. Cooley partners are among the global thought leaders addressing critical topics at the intersection of science, business and policy.

  • EU Pharmaceutical Law Forum 2022 

    Cooley partner Elisabethann Wright is a featured speaker at the EU Pharmaceutical Law Forum, and discusses the implications of the European Union’s Clinical Trials Regulation and Clinical Trials Information System.

  • ILTA Masterclass:<br> How can law firms and in-house counsel thrive in a sustainable environment? 

    Previously Recorded

    An International Legal Technology Association Masterclass brought together members of PwC, Burges Salmon and Cooley to share practical advice on improving your environmental, social and governance credentials in the context of day-to-day legal operations, as well as how to support clients and develop a responsible ESG strategy.

  • Post-COVID Employment: Remote Work, Office Return, Vaccine Mandates + Choice of Law Issues 


    Whether planning to move to a fully remote workplace or bringing back a workforce that has become accustomed to working from home, employers must be prepared to navigate a new set of challenges presented by COVID-19’s impact on workplace culture. Our speakers discuss what areas employers should be mindful of as they find their “new normal” in a post-COVID world.

  • NVCA Spotlight On Chicago 

    Cooley and the National Venture Capital Association have partnered up for a session featuring investors and leaders discussing the innovation ecosystem in the Chicago area.

  • 2022 Stanford Drug Discovery Symposium 

    Cooley partner Madhuri Roy is among the speakers at the 2022 Stanford Drug Discovery Symposium, which is intended for researchers, pharmaceutical companies, investment groups and those in the wider biomedical community, and covers advances in research and technology that have allowed for the discovery and testing of novel diagnostics and therapies.

  • Life Science Innovation Northwest 2022 

    Cooley lawyer Colleen Badgley served as a moderator at the Pacific Northwest’s largest annual life sciences conference, which brings together investors, public and private life sciences organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling life sciences breakthroughs of our time.

  • Panel Discussion on the UK NSI Act 

    Spotlight on the new UK national security screening regime

    The UK National Security and Investment Act (NSI Act) went into force on 4 January 2022, introducing a stand-alone investment screening regime with a mandatory filing for transactions falling within the scope of certain regulations and granting the government powers to investigate transactions on national security grounds. Lord Callanan, business minister responsible for act implementation, joins to discuss the regime.

  • Directors Forum Conference – Directors, Management and Shareholders in Dialogue 

    Cooley is proud to be an affiliate sponsor of the 17th annual Directors Forum Conference, which is brought to you by the Corporate Directors Forum and the Berkeley Center for Law and Business. Attendees will hear from directors, investors, management teams and corporate governance thought leaders regarding challenges and potential solutions in key areas such as supply chain, disruptive technologies, cyber ransom and artificial intelligence, as well as human capital management.

  • Deal-Makers: Trends for VC Investing in 2022 

    In the first installment of this four-part series, Cooley partner Peter Werner focuses on the outlook for venture capital investing in 2022 after a record-breaking year, considers which emerging industries are poised to make waves in the field and examines whether the public listing frenzy is here to stay.

  • Delaware Expands Use of Directors and Officers Captive Insurance 

    In February 2022, the Delaware General Corporation Law was amended to expressly allow the use of captive insurance companies to fund a Delaware corporation’s directors and officers insurance coverage. In this recorded event, Cooley lawyers provide an overview of insurance captives, formation and management, and how they can be used to help manage risk and, in some circumstances, create a source of revenue.

  • IGNITE Fire Pitch Competition 

    Cooley is a proud sponsor of Ignite Healthcare Network’s Fire Pitch Grand Final Competition – a high-energy annual pitch competition event where finalists from women-led medtech and digital health companies pitch to compete for investment prizes in front of an audience of respected healthcare executives and investors.

  • Digital Health Innovation Summit – West 

    Cooley is the lead sponsor of the inaugural Digital Healthcare Innovation Summit – West, which is a two-day forum for the top innovators, investors, payers, providers and policymakers driving the digital health revolution.

  • Preparing for and Winning Medical Device Patent Litigation 

    Previously Recorded

    Cooley IP litigators provide guidance to help your company prepare for and prevail in patent litigation in the medical device and diagnostics field – including best practices for offensive and defensive litigation matters, as well as thoughts on navigating transactions during pending litigation.

  • American Seed Trade Association Vegetable and Flower Seed Conference 2022 

    The 61st ASTA Vegetable & Flower Seed Conference featured networking and educational opportunities, as well as presentations on industry trends, global trade and tariff developments and more, including a panel with Cooley partner Dan Knauss.

  • Life Sciences in the Antitrust Hot Seat –<br> Trends and Guidance 

    Previously Recorded

    The US is seeing a substantial shift in the way politicians, government agencies and private plaintiffs approach antitrust enforcement – and life sciences companies are right in the crosshairs. Cooley antitrust thought leaders discuss key trends and strategies for navigating the changing enforcement landscape.

  • Launch Strong: Strategies for Enforcing and Protecting Brands Prior to Commercialization 

    Previously Recorded

    Don’t wait until product launch to take steps to strengthen and protect the mark from potential infringers, counterfeiters, and future litigants. This presentation will cover tools and cost-effective strategies for enforcing and strengthening potential trademarks prior to launch.

  • Future Food-Tech Summit 2022 

    Sponsored by Cooley, the Future Food-Tech Summit conference has become the annual meeting place for the global food-tech ecosystem, where food brands, active investors, startups and technology leaders come together to exchange insights, be inspired and identify future partners. Cooley partner Sonia Nath is one of panelists for 2022.

  • World Agri-Tech Innovation Summit 

    Cooley is sponsoring, and a Cooley partner will be a panelist, at this year’s hybrid World Agri-Tech Innovation Summit, which is the annual meeting place for the global agtech ecosystem. Growers, agribusiness leaders, technology pioneers and investors swap insights, get inspired and identify future partners among important delegations from Europe, Israel, Asia and Australia.

  • 2022 ABA Corporate Counsel CLE Seminar 

    Cooley is a proud sponsor of the three-day American Bar Association Corporate Counsel CLE Seminar, where in-house and outside counsel have come together each winter for more than 30 years to learn, network and share expertise about the unique challenges they face in representing corporations of all types.

  • Digital Health Investment Trends & 2022 Outlook 

    Previously Recorded

    In this Cooley Healthtech Talks webinar, leading venture capitalists give their digital health investments trends and predictions for 2022, and share their investment outlook and advice for entrepreneurs who are fundraising.

  • Trademark Law in 2021: Practical Trademark Perspectives from US and Canadian Counsel 

    During this program, a panel of thought leaders and professionals brought together by The Knowledge Group will guide you through recent developments in US trademark laws and notable court rulings.

  • Medical Device Investing 101 

    Presented by Alamo Angels and Biomed SA

    In this session, Carl Grant, executive vice president of global business development at Cooley, moderated a panel that featured Cooley lawyers Joshua Holleman and Kassity Mai. The program included a presentation on what to look for in a patent portfolio, and a discussion where company-side and investor-side leaders shared their unique perspectives on the benefits and risks of investing in a medical device startup.

  • WEBINAR<br>The Impact of Foreign Investment Screening Regimes on M&A Transactions 

    A Focus on the New UK Regime, with Key Learnings from  the US CFIUS Regime
    Previously Recorded

    Recent years have seen a proliferation of foreign investment screening and control regimes worldwide, and with them, heightened government scrutiny of foreign investment transactions. Implementation of foreign direct investment regimes has accelerated as national governments broaden their conceptions of national security issues and seek to protect an expansive range of industries and technologies.

  • Venture Capital & Private Equity Conference Series 

    Session Four

    This series was led by industry thought leaders from Cooley and PwC and covered tax, audit, legal and other relevant topics for finance and legal professionals at venture capital and private equity funds.

  • Hatch-Waxman 101: Pre-Suit Investigation and&nbsp;Diligence 

    Previously recorded

    This program was targeted at innovative life science companies that have filed, or will soon file, NDA or 505(b)(2) applications and are anticipating their first Hatch-Waxman litigation.

  • Reimagining a Post-Pandemic Workplace 

    Previously Recorded

    Employers under pressure to create and implement return-to-work policies and procedures need to consider where they are going before they decide how to get there – and this webinar provides a structured way to think through these issues while preparing for the future of your workplace.

  • Are You Ready for the Next Cyberattack? 

    Previously Recorded

    Cyberattacks are on the rise, with nearly every industry now facing cyber risk as attackers become adept at preying on users’ vulnerabilities through innovative social-engineering scams and other exposures. As company systems become more interconnected and dependent on third-party technologies, potential ripple effects of an attack have expanded considerably, while threat actors continue increasing amounts demanded from cyber extortion efforts.

  • Productwise – Liability in Times of Change for the Life Sciences Industry – Part Two 

    Life Sciences & Healthcare Innovation Program – Previously Recorded

    We examined significant liability risks for life sciences companies in the next 5-10 years, including the changing liability landscape, and risks in the context of emerging technologies.

  • Four New Years – Life Science Policy in the Biden-Harris Era 

    Life Sciences & Healthcare Innovation Program – Previously Recorded

    A discussion of the key issues, priorities and people shaping the life science policy and regulatory landscape in Washington, DC.

  • Hatch-Waxman 101 for the Emerging Life Science Company 

    Life Sciences & Healthcare Innovation Program – Previously Recorded

    This program was targeted at innovative life science companies that have filed, or will soon file, NDA or 505(b)(2) applications and are anticipating their first Hatch-Waxman litigation.

Biotech + Breaking Glass: Leading Women in Life Sciences

View our latest episode

Four Decades Driving Innovation in Healthcare and Life Sciences

Cooley is a global leader in the industry

Read more

In the Moment + Up to Date

Join our list to receive updates when new content of interest to life sciences and healthcare leaders is released

Subscribe Now

Cooley’s Life Sciences and Healthcare Innovation Program 2022

Program recordings are now available

View now